249 related articles for article (PubMed ID: 20808290)
1. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
Lun X; Chan J; Zhou H; Sun B; Kelly JJ; Stechishin OO; Bell JC; Parato K; Hu K; Vaillant D; Wang J; Liu TC; Breitbach C; Kirn D; Senger DL; Forsyth PA
Mol Ther; 2010 Nov; 18(11):1927-36. PubMed ID: 20808290
[TBL] [Abstract][Full Text] [Related]
2. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
Kim JH; Oh JY; Park BH; Lee DE; Kim JS; Park HE; Roh MS; Je JE; Yoon JH; Thorne SH; Kirn D; Hwang TH
Mol Ther; 2006 Sep; 14(3):361-70. PubMed ID: 16905462
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
5. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
7. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
9. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
[TBL] [Abstract][Full Text] [Related]
10. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Wang W; Tai CK; Kershaw AD; Solly SK; Klatzmann D; Kasahara N; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E25. PubMed ID: 16709031
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vaccinia virus for the treatment of cancer.
Guse K; Cerullo V; Hemminki A
Expert Opin Biol Ther; 2011 May; 11(5):595-608. PubMed ID: 21338330
[TBL] [Abstract][Full Text] [Related]
14. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
[TBL] [Abstract][Full Text] [Related]
15. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
[TBL] [Abstract][Full Text] [Related]
16. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
17. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH
J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776
[TBL] [Abstract][Full Text] [Related]
18. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
[TBL] [Abstract][Full Text] [Related]
19. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov NG; Fraefel C; Breakefield XO
Hum Gene Ther; 2000 Jul; 11(10):1429-38. PubMed ID: 10910140
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Heo J; Breitbach CJ; Moon A; Kim CW; Patt R; Kim MK; Lee YK; Oh SY; Woo HY; Parato K; Rintoul J; Falls T; Hickman T; Rhee BG; Bell JC; Kirn DH; Hwang TH
Mol Ther; 2011 Jun; 19(6):1170-9. PubMed ID: 21427706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
